Edap TMS reports HIFU revenue growth as US volume rises
The medical technology company reported an operating loss between $7.5 million and $8.5 million for the second quarter.
Edap TMS (FOCL), the medical technology provider, reported a significant expansion in its high-intensity focused ultrasound (HIFU) business for the second quarter ended June 30, 2026. The results reflect a strategic pivot toward its core technology as the company streamlined its reporting structure.
Revenue for the HIFU segment ranged between $12.7 million and $13.2 million, an increase of 34% to 39% compared to the same period in 2025. This growth was supported by a rise in gross margins, which reached between 54% and 56%, up 3% to 5% year-over-year.
Growth was driven largely by the Focal One system, with sales increasing 44% year-over-year to 13 systems. The global installed base of Focal One systems grew to 184 units, up from 146 systems in the second quarter of 2025.
Utilization of the technology also increased in the North American market. Focal One U.S. procedure volume grew 47% year-over-year during the quarter.
To align its financial reporting with its current strategy, Edap TMS shifted its legacy non-core ESWL and Distribution segments to discontinued operations effective the second quarter.
The company reported an operating loss between $7.5 million and $8.5 million for the period. As of June 30, 2026, cash, cash equivalents, and short-term investments totaled $21.5 million.
This liquidity position follows a €12.0 million draw in Tranche B borrowings from the company's European Investment Bank credit facility in April 2026.